A new online marketplace, aRukon, is set to launch this year to help researchers sell unused animal samples, aiming to reduce waste and prevent unnecessary animal deaths. Lundbeck’s experimental drug showed promise in slowing the progression of multiple system atrophy, despite missing the primary endpoint in a study. Other news includes BeiGene filing patent suits against Sandoz and MSN Group, and Novartis’ BTK inhibitor showing positive results in a dermatology trial.
Key takeaways:
- Amylyx Pharmaceuticals’ drug Relyvrio failed to show any benefit over a placebo in large clinical trials, leading to potential withdrawal from the market and raising questions about FDA's policy of “regulatory flexibility”.
- Alumis' lead drug candidate ESK-001 showed promising results in a Phase 2 trial for psoriasis, with plans to launch Phase 3 studies in the coming months.
- Over 100 scientists have signed a manifesto called “Responsible AI x Biodesign”, calling for safe and ethical handling of AI-mediated protein engineering to prevent potential use as bioweapons.
- A new online marketplace, aRukon, is launching globally to help researchers sell unused animal samples to other labs, aiming to reduce waste, save money, and prevent unnecessary animal deaths.